EBV as Therapeutic Target: A Pilot Study of Inducing and Targeting EBV-TK in EBV-Positive Lymphomas by Combination of Bortezomib and Ganciclovir.
Phase of Trial: Phase I
Latest Information Update: 03 Aug 2012
At a glance
- Drugs Bortezomib (Primary) ; Ganciclovir
- Indications Burkitt's lymphoma; Epstein-Barr virus infections; Hodgkin's disease; T cell lymphoma
- Focus Adverse reactions
- 11 Aug 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 18 Feb 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 22 Jul 2010 Planned end date (Jul 2011) added as reported by ClinicalTrials.gov.